HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Market For COVID Tests, Face Masks Likely To Last, Senators Suggest Requiring Efficacy Labeling

Executive Summary

Consumer Protection, Product Safety And Data Security Subcommittee hearing ventures past enforcement against false advertising for COVID-19 products and sales of fraudulently labeled products to criticism of e-commerce and social media providers for not keeping those products off their digital platforms.

You may also be interested in...



Expected Spread Of US OTC Diagnostics Could Change Consumers’ Health Care Behaviors

Diagnostics platform provider Ash Wellness expects at-home test providers can help improve consumers’ long-term health care outcomes with follow-up and ongoing communications for users of their products, influencing them to change behaviors.

Expected Spread Of US OTC Diagnostics Could Change Consumers’ Health Care Behaviors

Diagnostics platform provider Ash Wellness expects at-home test providers can help improve consumers’ long-term health care outcomes with follow-up and ongoing communications for users of their products, influencing them to change behaviors.

US FTC Diagnoses Omicron Symptom: More Fraudulent COVID-19 Treatment Claims

Agency says emergence of Omicron variant spurred marketers of products and services from peptide therapy to herbal remedies, and from nasal irrigation to intravenous drips to make false COVID-19 claims. 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel